Phase 2 Breast Cancer Trial, Not Yet Recruiting NCT07271992 Sponsor: First Hospital of China Medical University Condition: Breast Cancer
Back to Breast Cancer

Phase 2 Breast Cancer Trial, Not Yet Recruiting

NCT07271992
Not Yet Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • Participants must be 18 years of age or older.
  • Participants must have a confirmed diagnosis of stage II or III triple-negative breast cancer (a type of breast cancer that tests negative for certain receptors), confirmed through a tissue sample analysis.
  • Participants must have a good general health and activity level, rated 0 or 1 on a standard medical scale (meaning fully active or able to carry out light work).
  • A suitable tumour tissue sample must be available before the start of the trial.
  • Blood cell counts must meet certain levels without the help of growth factor support or blood transfusions: white blood cells, platelets, and red blood cells must all be within acceptable ranges (confirm with trial site for exact values).
  • Liver function must be within acceptable ranges, including bilirubin, ALT, and AST levels.
  • Kidney function must be within acceptable ranges, including creatinine levels.
  • Urine must show only a small or no amount of protein.
  • Blood clotting function must be within normal ranges; people already on blood-thinning medication may still be eligible if their clotting levels remain within the appropriate treatment range.
  • Levels of two pancreas-related substances in the blood (amylase and lipase) must be within acceptable ranges.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People with serious or uncontrolled illness, including active infections being treated with intravenous (drip) antibiotics, severe ongoing digestive problems with diarrhoea, active bleeding disorders, severe heart or mental health conditions, or a history of receiving a transplanted organ from another person.
  • People who have had another type of cancer in the past 3 years that is known to still be active, with some exceptions such as certain treated skin cancers or early-stage cancers that were fully removed (confirm with trial site).
  • People with a current or past history of autoimmune or inflammatory conditions (where the immune system attacks the body).
  • People whose cancer has spread to distant parts of the body.
  • People with active or uncontrolled hepatitis B or C, uncontrolled HIV infection, or active tuberculosis.
  • People with a history of lung inflammation conditions, including those caused by medications, radiation treatment, or previous immunotherapy.
  • People who have already had surgery, radiotherapy, or any systemic cancer treatment specifically for their triple-negative breast cancer.
  • People who have received immune-suppressing medications within 14 days before the first trial treatment.
  • People who have received a live attenuated vaccine (a type of vaccine made with a weakened live virus) within 30 days before the first trial treatment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 31 July 2026

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
First Hospital of China Medical University
Registry
ClinicalTrials.gov
Start date
15 December 2025
Est. completion
14 December 2030

Primary endpoints

pathological complete response (pCR) rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov